We are live on ! Find out more
SFM

Sphera Funds Management Portfolio holdings

AUM $630M
1-Year Est. Return 108.65%
This Fund
S&P 500
This Quarter Est. Return
+12.99%
1 Year Est. Return
+108.65%
3 Year Est. Return
+217.64%
5 Year Est. Return
+342.91%
10 Year Est. Return
+2,254.45%
AUM
$725M
AUM Growth
+$66.7M
Cap. Flow
+$16.4M
Cap. Flow %
2.26%
Top 10 Hldgs %
41.88%
Holding
145
New
38
Increased
32
Reduced
27
Closed
36

Top Buys

Rank Stock Value
1
GILD icon
Gilead Sciences
GILD
+$25.1M
2
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$19.4M
3
AMGN icon
Amgen
AMGN
+$17.7M
4
BLUE
bluebird bio
BLUE
+$12.8M
5
VTRS icon
Viatris
VTRS
+$11M

Top Sells

Rank Stock Value
1
CELG
Celgene Corp
CELG
+$28.5M
2
REGN icon
Regeneron Pharmaceuticals
REGN
+$14.3M
3
SHPG
Shire pic
SHPG
+$11.3M
4
FOLD
Amicus Therapeutics
FOLD
+$9.93M
5
SRPT icon
Sarepta Therapeutics
SRPT
+$9.8M

Sector Composition

Rank Sector Weight
1 Healthcare 72.21%
2 Technology 6.12%
3 Financials 1.97%
4 Industrials 1.58%
5 Consumer Discretionary 1.41%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
PVLA
51
Palvella Therapeutics
PVLA
$1.99B
$4.27M 0.59%
10,533
+533
+5% +$254K
EPZM
52
DELISTED
Epizyme, Inc
EPZM
$4.16M 0.57%
+307,154
New +$4.78M
SBBP
53
DELISTED
Strongbridge Biopharma plc.
SBBP
$4.04M 0.56%
+673,996
New +$4.93M
XENE icon
54
Xenon Pharmaceuticals
XENE
$6.06B
$4.04M 0.56%
+439,034
New +$2.73M
KZR
55
DELISTED
Kezar Life Sciences
KZR
$3.94M 0.54%
+22,790
New +$3.98M
CBIO
56
Crescent Biopharma
CBIO
$537M
$3.87M 0.53%
2,399
+899
+60% +$1.55M
META icon
57
Meta Platforms (Facebook)
META
$1.42T
$3.71M 0.51%
19,100
+13,003
+213% +$2.35M
GOOGL icon
58
Alphabet (Google) Class A
GOOGL
$4.36T
$3.69M 0.51%
65,380
-30,460
-32% -$1.66M
CRVS icon
59
Corvus Pharmaceuticals
CRVS
$1.12B
$3.69M 0.51%
335,987
+14,557
+5% +$162K
OBSV
60
DELISTED
ObsEva SA Ordinary Shares
OBSV
$3.69M 0.51%
243,669
-501,528
-67% -$6.66M
FLEX icon
61
Flex
FLEX
$41.7B
$3.67M 0.51%
344,786
-63,716
-16% -$715K
DCPH
62
DELISTED
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
$3.66M 0.5%
93,031
+52,185
+128% +$1.54M
PRQR icon
63
ProQR Therapeutics
PRQR
$243M
$3.6M 0.5%
493,749
-164,751
-25% -$831K
ABEO icon
64
Abeona Therapeutics
ABEO
$366M
$3.57M 0.49%
8,927
-2,873
-24% -$1.26M
EVOK
65
DELISTED
Evoke Pharma
EVOK
$3.53M 0.49%
9,798
+7,063
+258% +$2.65M
CSTE icon
66
Caesarstone
CSTE
$72.3M
$3.48M 0.48%
230,816
+218,621
+1,793% +$3.75M
ALNA
67
DELISTED
Allena Pharmaceuticals
ALNA
$3.48M 0.48%
267,349
-142,850
-35% -$2.06M
VRTX icon
68
Vertex Pharmaceuticals
VRTX
$121B
$3.4M 0.47%
+20,000
New +$3.1M
SRRA
69
DELISTED
Sierra Oncology, Inc. Common Stock
SRRA
$3.18M 0.44%
26,895
+1,895
+8% +$190K
ORLY icon
70
O'Reilly Automotive
ORLY
$72.9B
$2.97M 0.41%
162,660
– –
WIX icon
71
WIX.com
WIX
$2.3B
$2.96M 0.41%
+29,542
New +$2.63M
QTTB icon
72
Q32 Bio
QTTB
$466M
$2.89M 0.4%
7,880
+491
+7% +$176K
ELOX
73
DELISTED
Eloxx Pharmaceuticals, Inc. Common Stock
ELOX
$2.86M 0.39%
+4,187
New +$2.71M
FSCT
74
DELISTED
ForeScout Technologies, Inc. Common Stock
FSCT
$2.62M 0.36%
+76,400
New +$2.48M
LRCX icon
75
Lam Research
LRCX
$367B
$2.52M 0.35%
145,970
+12,410
+9% +$239K
1 2
3
4 5

Similar funds

VIM
Vancity Investment Management Vancouver, British Columbia, Canada $629M AUM 2.49% 1-Year Est. Return
KCMH
Keywise Capital Management (HK) Hong Kong $630M AUM 81.01% 1-Year Est. Return
FCFC
First Commonwealth Financial Corp Indiana, Pennsylvania $629M AUM 20.47% 1-Year Est. Return
BI
BlueSpruce Investments Chicago, Illinois $631M AUM 11.83% 1-Year Est. Return
PWW
Pettyjohn Wood & White Lynchburg, Virginia $628M AUM 20.96% 1-Year Est. Return
TTSTC
Texas Treasury Safekeeping Trust Company Austin, Texas $628M AUM 15.58% 1-Year Est. Return
SWP
Summit Wealth Partners Orlando, Florida $632M AUM 9.71% 1-Year Est. Return
EIM
Essex Investment Management Boston, Massachusetts $632M AUM 95.36% 1-Year Est. Return

Sphera Funds Management's Q2 2018 Portfolio in Review

As of Q2 2018, Sphera Funds Management held 145 positions worth $725M, up 10% from $659M the previous quarter. Its ten largest holdings account for 42% of the portfolio.

Sphera Funds Management's Q2 2018 filing shows 38 new, 32 increased, 27 reduced and 36 closed positions. Its largest new stake was Gilead Sciences: 355,000 shares worth $25.1M. The largest sale was Celgene Corp, an estimated $28.5M.

By sector, the portfolio is most concentrated in Healthcare at 72% of assets, down from 75% a quarter earlier, followed by Technology and Financials.

  • Sphera Funds Management's largest Q2 2018 buy was Gilead Sciences: 355,000 shares worth $25.1M.
  • Sphera Funds Management added most to Viatris in Q2 2018, an estimated $11M increase.
  • Sphera Funds Management's biggest Q2 2018 reduction was Shire pic, cutting an estimated $11.3M.
  • Sphera Funds Management fully exited Celgene Corp in Q2 2018, selling an estimated $28.5M.
  • Sphera Funds Management's ten largest holdings make up 42% of its $725M portfolio in Q2 2018.
  • Sphera Funds Management opened 38 new positions and closed 36 in Q2 2018.
  • Sphera Funds Management's portfolio value rose 10% quarter-over-quarter to $725M.

Based on Sphera Funds Management's 13F filing for Q2 2018, filed 13 Aug 2018.